symptomatische patiënten met een verhoogd risico op een eerste psychose psychosis ultra high risk for developing psychosis
Conditions
Interventions
Condition 1: fishoil and cognitive behavioural therapy plus casemanagement
Condition 2: placebo and cognitive behavioural therapy plus casemanagement
Sponsors
Orygen Youth Health Research Centre
Eligibility
Age
12 Years to 99 Years
Inclusion criteria
Inclusion criteria: A. General inclusion criteria: i. Ability to give informed consent Where participants are of legal childhood age, consent will also be obtained from one of the participant*s parents. Both the parent and participant will be required to sign the consent form in such a case. It will be the investigator*s responsibility to determine whether a participant of legal childhood age has the capacity to consent to the study. ii. Age 13 - 40 yrs B. Membership of one of the following *at-risk* groups: i. Vulnerability (Trait and State Risk Factor) Group: Individuals with a combination of a trait risk factor (schizotypal personality disorder or a family history of psychotic disorder in a first degree relative) and a significant deterioration in mental state and/or functioning or sustained low functioning during the past year. ii. Attenuated Psychotic Symptoms (APS) Group: Individuals with subthreshold (intensity or frequency) positive psychotic symptoms. The symptoms must have been present during the past year and be associated with a significant reduction in or sustained low functioning. iii. Brief Limited Intermittent Psychotic Symptoms Group (BLIPS): Individuals with a recent history of frank psychotic symptoms that resolved spontaneously (without antipsychotic medication) within one week. The symptoms must have been present during the past year and be associated with a significant reduction in or sustained low functioning.
Exclusion criteria
Exclusion criteria: i. Past history of a treated or untreated psychotic episode of one week*s duration or longer ii. Organic brain disease, e.g. epilepsy, inflammatory brain disease iii. Abnormal coagulation profile parameters or thyroid function test results >10% above or below the limits of the normal range. iv. Any physical illness with psychotropic effect, if not stabilized v. Current treatment with lithium, methyl phenidate or ketamine, or recreational use of ketamine. vi. Past neuroleptic exposure equivalent to a total lifetime haloperidol dose of >50 mg. [Refer to Appendix IV for a list of equivalent doses for other neuroleptic agents.] vii. Diagnosis of a serious developmental disorder, e.g. Asperger's syndrome viii. Premorbid IQ than 4 weeks of regular omega-3 supplementation (>2 capsules standard strength providing >600 mg combined EPA/DHA) within the last 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transition to psychosis | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of symptoms Level of functioning | — |
Countries
Netherlands
Outcome results
None listed